(Total Views: 549)
Posted On: 10/15/2020 5:43:05 PM
Post# of 153771
“Dr. Seethamraju's statement on Oct 7 that the "FDA is reviewing CD12 unblinded data" impacts the schedule if true.”
I thought the S/C data would only be reviewed by the FDA if the DSMB recommended that the trial be halted? What other reason would the FDA have to review the data?
I thought the S/C data would only be reviewed by the FDA if the DSMB recommended that the trial be halted? What other reason would the FDA have to review the data?
(0)
(0)
